INR VALUES WITH PATIENTS ON ORAL ANTICOAGULANT THERAPY DURING COVID-19 PANDEMICS
DOI:
https://doi.org/10.5457/ams.v53i1.670Keywords:
warfarin, acenocoumarol, COVID-19 pandemicsAbstract
Introduction: Oral anticoagulant therapy (OAT) is widely used for preventing and treating vein and arterial thrombosis. The OAT drug that is most commonly used is warfarin.
Aim of the paper: assess the effect of anti-pandemic measures on the frequency of disorders in INR values with patients who use warfarin.
Material and methods: This study includes 89 patients who use warfarin and who controlled their INR values University Clinical Center Tuzla. The available data base gave information about the patients including age, gender, diagnosis and INR values during 2019 and 2020 and these were compared.
Results: Among 89 examinees there were 57.3% (51) male patients and 42.7% (38) female patients. From the overall number of patients during 2019 51.7% (46) patients had recommended INR values while in 48.3% (43) patients there were INR oscillations outside the therapeutic range of warfarin effect. The average INR value in 2019 was 2.6 while in 2020 it was 1.7. The disorders of INR outside therapeutic range (INR<2.0 i INR>3.5) during 2019 was noticed in 21.3% (19), and in 2020 in 35.9% (32) patients. The results showed that 68.5% patients during pandemics didn’t regulate INR values.
Conclusion: The results of the examinations showed that the appearance of the COVID-19 pandemics resulted in the disorder of INR values with 61 (68.5%) patients who use warfarin regardless of the indication for usage, which is 20.2% higher in comparison to 2019.
Key words: warfarin, acenocoumarol, COVID-19 pandemics
Downloads
Published
Issue
Section
License
Copyright transfer
The listed authors warrant that they are the authors and sole owners of the submitted manuscript. The authors also warrant that the work is original; that it has not been previously published in print or electronic format and is not under consideration by another publisher or electronic medium; that it has not been previously transferred, assigned, or otherwise encumbered; and that the authors have full power to grant such rights. With respect to the results of this work, the manuscript of this or substantially similar content will not be submitted to any other journal until the review process in the Acta Medica Salinianana has been officially completed (acceptance or rejection of the manuscript). The paper will not be withdrawn from the review process by the Acta Medica Saliniana Editorial Board until the review process is completed. The authors will comply with the requests of the Acta Medica Saliniana Editors and reviewers to improve the paper for publication. The eventual disagreements will be submitted in a written form; the authors are aware that the disagreement(s) with the Acta Medica Saliniana requests may result in the rejection of the manuscript. The authors hereby grant to the Acta Medica Saliniana the right to edit, revise, abridge, and condense the manuscript. If the manuscript is accepted for publication in the Acta Medica Saliniana, the authors hereby transfer the copyright of the paper to the Acta Medica Saliniana. The authors permit the Acta Medica Saliniana to allow third parties to copy any part of the journal without asking for permission, provided that the reference to the source is given. For papers with more than one author: All other co-authors agree to allow the corresponding author to make decisions regarding prepublication release of the information in the paper to the media, federal agencies, or both.
